|
Mutation Information
|
Mutation Site
|
K103N |
|
Mutation Type
|
Amino acid level |
|
Gene/Protein/Region Type
|
RT |
|
Relevant Drug
|
INSTIs;NRTIs;dolutegravir (DTG);NNRTIs;raltegravir (RAL) |
Literature Information
|
PubMed PMID
|
27539455
|
|
Published Year
|
2016 |
|
Journal
|
Infectious diseases and therapy |
|
Title
|
New Antiretroviral Treatment for HIV. |
|
Author
|
Badowski ME,Pérez SE,Biagi M,Littler JA |
|
Evidence
|
No INSTI or NRTI resistance was identified at 144 weeks in the dolutegravir + lamivudine/abacavir group, whereas seven participants developed resistance to efavirenz/emtricitabine/tenofovir disoproxil fumarate [n = 6 NNRTI mutations (K101E, K103 K/N, and G190G/A);n = 1 NRTI mutation (K65 K/R)]. For treatment-experienced, INSTI-naive individuals, once-daily dolutegravir 50 mg was compared to twice-daily raltegravir 400 mg along with two additional investigator-selected ARVs.
|
|
|
HIV Mutation Detail Information